Alexion took a pair of steps toward further rebuilding its pipeline Wednesday, gaining rights to targets in the complement pathway via a deal with Zealand and adding a clinical-stage molecule from Affibody for IgG-mediated autoimmune...

Eli Lilly and Co. (NYSE:LLY) partnered with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies to treat cardiometabolic disorders, neurodegeneration and pain. The deal is the second RNAi collaboration Dicerna has made within...

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) entered into the RNAi field with a deal with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies for complement-mediated diseases. Alexion also reported higher-than-expected revenues and sales of Soliris...

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) entered into the RNAi field with a deal with Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) to discover and develop RNAi therapies for complement-mediated diseases. Alexion also reported higher-than-expected revenues and sales of Soliris...

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) reported interim six-week data from the Phase I PHYOX trial showing that single subcutaneous doses of DCR-PHXC brought urinary oxalate levels into the normal or near-normal range in five of eight...

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) said on April 20 it has resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing. In 2015, Alnylam filed a suit...